Crossmark

Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study

Published Print: 2024-05

Authors

Wang, Z.

Bi, H.

Wang, Y.D.

Liu, Q.

Shao, B.

Li, C.Q.

Fu, C.

Fu, S.

Shan, G.Y.

Chen, A.

Lv, C.C.

Zeng, Y.
License Information

Text and Data Mining valid from 2024-05-01

Text and Data Mining valid from 2024-05-01
More Information

This article is maintained by: Elsevier

Article Title: Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study

Journal Title: Actas Urológicas Españolas (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.acuroe.2023.12.006

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.acuro.2023.10.010

Content Type: article

Copyright: © 2023 Published by Elsevier España, S.L.U. on behalf of AEU.

Document is current